Xeris Biopharma Holdings, Inc. (FRA:2B30)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.37B +28.0% |
| Revenue (ttm) | 293.59M +36.3% |
| Net Income | -15.02M |
| EPS | -0.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 39.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 7.37 |
| Previous Close | 7.31 |
| Day's Range | 7.37 - 7.37 |
| 52-Week Range | 4.48 - 8.48 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Xeris Biopharma Holdings
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patient... [Read more]
News
Xeris Announces Details for XP-8121 Program Overview Webinar
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma price target raised to $12 from $9 at Barclays
Barclays raised the firm’s price target on Xeris Biopharma (XERS) to $12 from $9 and keeps an Overweight rating on the shares after meeting with management. The firm left with…
Xeris Biopharma Holdings Earnings Call Transcript: Q2 2026
Q2 delivered record revenue growth of 34% year-over-year, led by RECORLEV's 81% surge and strong rebounds from Gvoke and KEVEYIS. The company strengthened its IP portfolio, fully retired convertible notes, and raised 2026 revenue guidance to $385M-$390M.
Xeris Biopharma Holdings Earnings release: Q2 2026
Xeris Biopharma Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Xeris Biopharma Holdings Quarterly report: Q2 2026
Xeris Biopharma Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Xeris Biopharma tightens FY26 revnue view $385M-$390M, consensus $385.94M
07:11 EDT Xeris Biopharma (XERS) tightens FY26 revnue view $385M-$390M, consensus $385.94M
Xeris Biopharma Reports Second Quarter 2026 Financial Results
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The...
Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing...
Xeris Biopharma appoints CEO John Shannon as chair of the board
Xeris Biopharma (XERS) announced that its Board of Directors appointed John Shannon to Chair of the Board, in addition to his role as CEO, effective July 1. Shannon succeeds Marla…
Xeris Announces Updates to Its Board of Directors
CHICAGO--(BUSINESS WIRE)--Xeris Announces Updates to Its Board of Directors.
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient liv...
Xeris Biopharma announces private exchange of convertible notes
Xeris Biopharma (XERS) entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028. Pursuant to the exchange agreements, Xeris h...
Xeris Biopharma Announces Private Exchange of Convertible Notes
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference 2026
Revenue grew 43% in Q1, driven by RECORLEV, with expanded commercial reach and strong new patient growth. XP-8121 is advancing to phase III, targeting a 2030 launch. Patent protection for RECORLEV extends to 2040, and financial strength supports ongoing investment.
Xeris Biopharma Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 43% net product revenue growth, led by RECORLEV's 95% surge and strong KEVEYIS performance, while GVOKE was flat due to Medicare headwinds. Full-year revenue guidance was raised, and commercial expansion is expected to drive further growth.
Xeris Biopharma Holdings Earnings release: Q1 2026
Xeris Biopharma Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Xeris Biopharma Holdings Quarterly report: Q1 2026
Xeris Biopharma Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Xeris Biopharma Reports First Quarter 2026 Financial Results
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS.
Xeris Biopharma Holdings Proxy statement: Proxy filing
Xeris Biopharma Holdings filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Xeris Biopharma Holdings Proxy statement: Proxy filing
Xeris Biopharma Holdings filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
Revenue grew 44% to $292 million in 2025, with RECORLEV driving growth and a strong pipeline led by XP-8121 entering phase III. Investments in commercial expansion and R&D are expected to sustain momentum, while robust IP and a strengthened balance sheet support long-term targets.